{"title":"CD47 Protein: Target Overview, Research Applications, and Selection Guide","description":"","products":[{"product_id":"recombinant-rhesus-macaque-cd47-protein-his-flag-tag-bl-2165np","title":"Recombinant Rhesus Macaque CD47 Protein (N-6His-Flag)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rhesus macaque Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Glu141 is expressed with a 6His, Flag tag at the N-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"F7A802\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/F7A802\/entry\"\u003eF7A802\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47, also known as Integrin‑Associated Protein (IAP) and OA3, is a glycosylated atypical member of the immunoglobulin superfamily. Mouse CD47 is an integral membrane protein that consists of a extracellular domain (ECD) with a single Ig‑like domain, five membrane-spanning regions with short intervening loops, and C‑terminal cytoplasmic tail. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus. As a receptor for SIRPA, it binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cellcell adhesion, it enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. It may play a role in membrane transport and\/or integrin dependent signal transduction. It also prevents premature elimination of red blood cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e33-55 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915047403745,"sku":"BL-2165NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLRKAIci7AACJ8a1DYvg760_9dcc4bdc-dba3-40ba-9f32-88c732e8ba8f.jpg?v=1685851469"},{"product_id":"recombinant-human-cd47-protein-fc-tag-bl-0014np","title":"Recombinant Human CD47 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e40.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915041046753,"sku":"BL-0014NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLXyAWhelAACfhBR6edU481_d7770133-c2b4-425d-b8fa-36df91efeffd.jpg?v=1685851258"},{"product_id":"recombinant-mouse-cd47-protein-fc-tag-bl-0144np","title":"Recombinant Mouse CD47 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro158 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q61735-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q61735\/entry#Q61735-2\"\u003eQ61735-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47, also known as Integrin‑Associated Protein (IAP) and OA3, is a glycosylated atypical member of the immunoglobulin superfamily. Mouse CD47 is an integral membrane protein that consists of a extracellular domain (ECD) with a single Ig‑like domain, five membrane-spanning regions with short intervening loops, and C‑terminal cytoplasmic tail. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus. As a receptor for SIRPA, it binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cellcell adhesion, it enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. It may play a role in membrane transport and\/or integrin dependent signal transduction. It also prevents premature elimination of red blood cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e42.8 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-90 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915037901025,"sku":"BL-0144NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZqAXBWGAACn0VJBC7c391_bba4c22e-8d3d-4f89-97ea-b7442b5748f2.jpg?v=1685851159"},{"product_id":"recombinant-human-cd47-protein-his-tag-bl-0402np","title":"Recombinant Human CD47 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e14.76 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30-45 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 10mM Tris-Citrate, 150mM NaCl, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915016569057,"sku":"BL-0402NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLUCAP1cVAACtbMvMsLc666_177557f0-45b3-41ec-869a-dfba5dd9cbe0.jpg?v=1685850602"},{"product_id":"recombinant-mouse-cd47-protein-his-tag-bl-1122np","title":"Recombinant Mouse CD47 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro158 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q61735-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q61735\/entry#Q61735-2\"\u003eQ61735-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47, also known as Integrin‑Associated Protein (IAP) and OA3, is a glycosylated atypical member of the immunoglobulin superfamily. Mouse CD47 is an integral membrane protein that consists of a extracellular domain (ECD) with a single Ig‑like domain, five membrane-spanning regions with short intervening loops, and C‑terminal cytoplasmic tail. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus. As a receptor for SIRPA, it binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cellcell adhesion, it enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. It may play a role in membrane transport and\/or integrin dependent signal transduction. It also prevents premature elimination of red blood cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e16.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30-60 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915046125793,"sku":"BL-1122NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLamAbsjsAAC4N8U5kYY287_bf110223-6d5d-40c3-9550-75f5088f611b.jpg?v=1685851421"},{"product_id":"recombinant-human-cd47-protein-fc-avi-tag-bl-1987np","title":"Biotinylated Human CD47 Protein (C-Fc-Avi)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiotinylated Recombinant Human Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a human IgG1 Fc, Avi tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47; Antigenic surface determinant protein OA3; Integrin-associated protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e42.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-70 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20μg","offer_id":43915034951905,"sku":"BL-1987NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLayACDIBAACv9mJlC0U511_0f01feb7-bc80-40e4-b191-9e481d342274.jpg?v=1685851080"},{"product_id":"recombinant-human-cd47-protein-fc-tag-bl-2149np","title":"Recombinant Human CD47 Protein (C-mFc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a mouse IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47; Antigenic surface determinant protein OA3; Integrin-associated protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e40.3 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e48-65 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915053990113,"sku":"BL-2149NP","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"biotinylated-human-cd47-c-avi-6his-bl-2622np","title":"Biotinylated Human CD47 Protein (C-Avi-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiotinylated Recombinant Human Leukocyte Surface Antigen CD47 is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a Avi, 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e16.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30-40 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 10mMTris-Citrate, 150mM NaCl, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20μg","offer_id":43911646118113,"sku":"BL-2622NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLcKAClp1AACP5FQvkhc898.jpg?v=1685850154"},{"product_id":"recombinant-rhesus-macaque-cd47-c-fc-bl-2686np","title":"Recombinant Rhesus Macaque CD47 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rhesus Macaque CD47 Molecule is produced by our Mammalian expression system and the target gene encoding Gln19-Pro139 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"F7A802\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/F7A802\/entry\"\u003eF7A802\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Protein; IAP; Protein MER6; CD47; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47(Integrin-Associated Protein,IAP) is a 40 ‑ 60 kDa variably glycosylated atypical member of the immunoglobulin superfamily. The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells. CD47 is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The protein is also a receptor for the C-terminal cell-binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This protein has broad tissue distribution, and is reduced in expression on Rh erythrocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e40.8 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-90 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 50 mM Tris-HCl, 100 mM Glycine, pH 7.5.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43911652901089,"sku":"BL-2686NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWqAcz1sAACbGmQooos330.jpg?v=1685850245"},{"product_id":"recombinant-human-leukocyte-surface-antigen-cd47-cd47-protein-hfc-active-blc-05575p","title":"Recombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc), Active is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/ug as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Measured by its binding ability in a functional ELISA. Immobilized SIRPA  at 2 μg\/ml can bind human CD47, the EC 50 of human CD47 protein is 65.91-82.42 ng\/ml. 2. Human SIRPA protein His\/Myc tag  captured on COOH chip can bind Human CD47 protein Fc tag  with an affinity constant of 19.1 nM as detected by LSPR Assay.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q08722          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAntigenic surface determinant protein OA3(Integrin-associated protein)(IAP)(Protein MER6)(CD47)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e41.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998936727777,"sku":"BLC-05575P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP004940HU-SDS.jpg?v=1690563400"},{"product_id":"recombinant-human-leukocyte-surface-antigen-cd47-cd47-protein-hfc-active-blc-05627p","title":"Recombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc), Active is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe ED50 as determined by its ability to bind Human SIRPA in functional ELISA is less than 200 ng\/ml.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q08722          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAntigen identified by monoclonal 1D8; Antigenic surface determinant protein OA3; CD 47; CD47; CD47 antigen (Rh-related antigen; integrin-associated signal transducer); CD47 antigen; CD47 glycoprotein; CD47 molecule; CD47_HUMAN; IAP; Integrin Associated Protein; Integrin associated signal transducer; Integrin-associated protein; Leukocyte surface antigen CD47; MER 6; MER6; OA 3; OA3; OTTHUMP00000041152; OTTHUMP00000041153; Protein MER6; Rh related antigen; Surface antigen identified by monoclonal 1D8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e40.8 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered 20 mM PB, 150 mM NaCl, pH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998941839585,"sku":"BLC-05627P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP005211HU.jpg?v=1690511541"},{"product_id":"recombinant-human-leukocyte-surface-antigen-cd47-cd47-protein-his-active-blc-05628p","title":"Recombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (His), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (His), Active is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe ED50 as determined by its ability to bind Human SIRPA in functional ELISA is less than 20 ug\/ml.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q08722          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAntigen identified by monoclonal 1D8; Antigenic surface determinant protein OA3; CD 47; CD47; CD47 antigen (Rh-related antigen; integrin-associated signal transducer); CD47 antigen; CD47 glycoprotein; CD47 molecule; CD47_HUMAN; IAP; Integrin Associated Protein; Integrin associated signal transducer; Integrin-associated protein; Leukocyte surface antigen CD47; MER 6; MER6; OA 3; OA3; OTTHUMP00000041152; OTTHUMP00000041153; Protein MER6; Rh related antigen; Surface antigen identified by monoclonal 1D8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e14.76 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered 10 mM Tris-Citrate, 150 mM NaCl, pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998941970657,"sku":"BLC-05628P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP005201HU.jpg?v=1690511545"},{"product_id":"recombinant-mouse-leukocyte-surface-antigen-cd47-cd47-protein-his-active-blc-05697p","title":"Recombinant Mouse Leukocyte Surface Antigen Cd47 (CD47) Protein (His), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Leukocyte Surface Antigen Cd47 (CD47) Protein (His), Active is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe ED50 as determined by its ability to bind Mouse SIRPA in functional ELISA is less than 20 ug\/ml.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q61735          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCd47; Leukocyte surface antigen CD47; Integrin-associated protein; IAP; CD antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMus musculus (Mouse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQLLFSNVNSIEFTSCNETVVIPCIVRNVEAQSTEEMFVKWKLNKSYIFIYDGNKNSTTTDQNFTSAKISVSDLINGIASLKMDKRDAMVGNYTCEVTELSREGKTVIELKNRTAFNTDQGSACSYEEEKGGCKLVSWFSP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19-158aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial of Isoform 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e16.7 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered 1xPBS, pH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16423           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29105884            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Our results support an intrinsic role of CD47 in ovarian cancer progression and immune evasion            \u003ca rel=\"nofollow\"\u003e             PMID:                        28380460            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mice deficient in CD47 (CD47 Knockout) had significantly less brain neutrophil infiltration at 24h, upregulated VEGF expression in peri-lesion cortex at 7 and 14day            \u003ca rel=\"nofollow\"\u003e             PMID:                        27931776            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TSP1 significantly accelerates replicative senescence and associated cell cycle arrest in a CD47-dependent manner.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27607583            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47, TSP1, and to a lesser extent SIRPalpha facilitate exosome-mediated myeloid-derived suppressor cells chemotaxis and migration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27728760            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings have demonstrated how tumor cells inhibit innate sensing in dendritic cells and suggested that the CD47-SIRPalpha axis is critical for dendritic cell-driven antitumor immunity            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801234            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27283989            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Treg cells protect dopaminergic neurons against MPP+ neurotoxicity by a cell-to-cell contact mechanism underlying CD47-SIRPA interaction and Rac1\/Akt activation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28268219            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 deficient mice with vaccination showed greater protective efficacy against lethal challenge.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27194758            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results indicate an important role for CD47-SIRPalpha interactions in innate control of malaria and suggest novel targets for intervention.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091932            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythrocyte CD47 has a key role in hematoma clearance after intracerebral hemorrhage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26732568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicate that CD47 plays protective roles against disseminated candidiasis and alters pro-inflammatory and immunosuppressive pathways known to regulate innate and T cell immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26010544            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 deficiency ameliorates lupus nephritis in Fas(lpr) mice via suppression of IgG autoantibody production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26095930            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the cell adhesion molecule CD47 participates in multiple phases of granule cell development, including proliferation, migration, and neurite differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25288019            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Taken together, these data revealed a novel role for CD47 in the development of obesity and its related metabolic complications.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747123            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            NF KB mediated CD47 up regulation promotes sorafenib resistance treating hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25902734            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings prove that the TSP-1\/CD47\/SIRP-alpha signal axis is important to the evolution of tumor cells in the microenvironment of immunotherapy and identify thrombospondin-1 as a key signal            \u003ca rel=\"nofollow\"\u003e             PMID:                        25697354            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840925            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the microglial proinflammatory response to Abeta(1-42) protofibril is not dependent on CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        25451248            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression in the microenvironment was sufficient to limit tumor radiosensitivity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25297630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            role in promoting left ventricular heart failure by CaKMII-mediated up-regulation of HDAC3            \u003ca rel=\"nofollow\"\u003e             PMID:                        24922625            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphism in the innate immune receptor SIRPalpha controls CD47 binding and autoimmunity in the nonobese diabetic mouse.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25305319            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            using a syngeneic mouse hepatocyte transplantation model, the present study demonstrates that missing CD47 on donor cells alone can cause recipient myeloid cell activation and graft loss.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23394628            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            sought to investigate the effect of Hsp70-peptide complex on the expression of CD172alpha and CD47 receptors in normal peritoneal macrophages (NMO)            \u003ca rel=\"nofollow\"\u003e             PMID:                        24684700            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            'clustering' SIRPalpha into plasma membrane microdomains is essential for activated monocytes and macrophages to effectively interact with CD47 and initiate intracellular signaling            \u003ca rel=\"nofollow\"\u003e             PMID:                        24143245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Thrombospondin-1 signaling through CD47 is the first identified endogenous inhibitor of H2S signaling and constitutes a novel mechanism that negatively regulates T cell activation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23499828            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that lack of CD47 strongly impairs SIRPalpha-dependent osteoblast differentiation, deteriorate bone formation, and cause reduced formation of osteoclasts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23990469            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Thus, CD47 antagonists enable cell self-renewal and reprogramming by overcoming negative regulation of c-Myc and other stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23591719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 deficiency confers cell survival through the activation of autophagic flux and identifies CD47 blockade as a pharmacological route to modulate autophagy for protecting tissue from radiation injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22874555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inhibitor of apoptosis proteins (IAPs) and their antagonists regulate spontaneous and tumor necrosis factor (TNF)-induced proinflammatory cytokine and chemokine production            \u003ca rel=\"nofollow\"\u003e             PMID:                        23275336            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 deficiency promotes nerve fiber growth from cultured ventral mesencephalic dopamine neurons.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23049778            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although polymorphonuclear neutrophil (PMN) transmigration is not delayed in CD47-deficient mice, fewer neutrophils are found in the intestine at the postacute\/chronic stage of chronic colitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23203922            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47(low) status on CD4 effectors is necessary for the contraction\/resolution of the immune response in humans and mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22870271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23087362            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ectopic expression of murine Cd47 in human hepatocytes selectively favors engraftment upon transplantation into mice, a finding that should have a profound impact on the generation of robust humanized small animal models.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22535707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22859854            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engagement of endothelial CD47 by its ligands triggers outside-in signals in endothelium, facilitating leukocyte transendothelial migration at sites of inflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22815286            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that CD47(-\/-) mice are refractory to experimental autoimmune encephalomyelitis (EAE).            \u003ca rel=\"nofollow\"\u003e             PMID:                        22734047            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22215724            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47(high) status on CD4 T cells identifies functional long-lived memory T cell progenitors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22461697            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 signalling is dispensable for oral tolerance induction, whereas the expression of CD47 by non-haematopoietic cells is required for intestinal IgA B-cell responses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22070457            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            provides a rational basis for targeting CD47-SIRPalpha interactions, using for instance the antagonistic antibodies against human SIRPalpha described herein, to potentiate the clinical effects of cancer therapeutic antibodies            \u003ca rel=\"nofollow\"\u003e             PMID:                        22042861            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 deletion improves functional recovery from spinal cord injury via an increase in vascular patency, functional locomotor improvements and greater white matter sparing.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21168495            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998949343457,"sku":"BLC-05697P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP005351MO.jpg?v=1690511710"},{"product_id":"biotinylated-recombinant-human-leukocyte-surface-antigen-cd47-cd47-protein-hfc-avi-blc-06354p","title":"Biotinylated Recombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc-Avi)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiotinylated Recombinant Human Leukocyte Surface Antigen Cd47 (CD47) Protein (hFc-Avi) is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q08722          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFC-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e43.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            1682           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601028           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:961           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000355361           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28378740            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28968355            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29367423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25914268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29042481            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27411490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte\/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self\/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28393401            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863402            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28801364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27856600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28100392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27742621            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation\/self-renewal.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27259369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Engineering macrophages to eat cancer: from \"marker of self\" CD47 and phagocytosis to differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28522599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1\/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27349907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28076333            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages\/M2 were independently related to shorter survivals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27322955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27232934            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms            \u003ca rel=\"nofollow\"\u003e             PMID:                        26446381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27714815            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27855370            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that microglial activation may be partially caused by CD47\/signal regulatory protein-alpha- and CD200\/CD200R-mediated reductions in the immune inhibitory pathways            \u003ca rel=\"nofollow\"\u003e             PMID:                        27095555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27091975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest a reduction in the CD47 antigen\/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        26573233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'            \u003ca rel=\"nofollow\"\u003e             PMID:                        27437576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26093091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26116271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26077800            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25593301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26512116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25717063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        26311851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25747479            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26085683            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not            \u003ca rel=\"nofollow\"\u003e             PMID:                        25943033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Velcro\" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25837251            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report poor prognosis\/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25230070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24840181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24887393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression is induced following EBV infection of B cells; ligation cases G1 arres            \u003ca rel=\"nofollow\"\u003e             PMID:                        24911792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 regulates the epigenetic code by targeting UHRF1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25550546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25001859            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47            \u003ca rel=\"nofollow\"\u003e             PMID:                        24848268            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 associates with and regulates VEGFR2 in T cells.  CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25200950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS\/PAR2 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24523067            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24726056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24006483            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999027331297,"sku":"BLC-06354P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP004940HUj8-B-SDS.jpg?v=1690513807"},{"product_id":"recombinant-human-cd47-protein-active-blk-00054p","title":"Recombinant Human CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human CD47 Protein is expressed from HEK293 without tag.It contains Gln19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q08722\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNo Tag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 13.72 kDa. Due to glycosylation, the protein migrates to 35-48 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human CD47, No Tag at 5ug\/ml (100ul\/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 0.24ug\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123150840033,"sku":"BLK-00054P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230905143940.png?v=1715128114"},{"product_id":"biotinylated-human-cd47-protein-blk-00151p","title":"Biotinylated Human CD47 Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human CD47 Protein is expressed from HEK293 with hFc tag and Avi tag at the C-terminus.It contains Gln19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q08722\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 42.61 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123154542817,"sku":"BLK-00151P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20231107155437.png?v=1715128372"},{"product_id":"recombinant-rat-cd47-protein-active-blk-00252p","title":"Recombinant Rat CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat CD47 Protein is expressed from HEK293 with hFc tag at the C-terminus.It contains Gln19-Lys140.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P97829\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Lys140\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 40.40 kDa. Due to glycosylation, the protein migrates to 50-70 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Mouse SIRP alpha, His Tag at 2ug\/ml (100ul\/well) on the plate. Dose response curve for Rat CD47, hFc Tag with the EC50 of 29.8ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123159392481,"sku":"BLK-00252P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230824091506.png?v=1715128689"},{"product_id":"recombinant-cynomolgus-rhesus-macaque-cd47-protein-active-blk-00995p","title":"Recombinant Cynomolgus\/Rhesus macaque CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Cynomolgus\/Rhesus macaque CD47 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln19-Glu141.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e F7A802\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCynomolgus\/Rhesus macaque\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Glu141\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 15 kDa. Due to glycosylation, the protein migrates to 45-65 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Cynomolgus\/Rhesus macaque CD47, His Tag at 5ug\/ml (100ul\/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 0.11ug\/ml determined by ELISA (QC Test). The affinity constant of 63.27 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123207758049,"sku":"BLK-00995P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20220904112231.png?v=1715131003"},{"product_id":"recombinant-mouse-cd47-protein-active-blk-02446p","title":"Recombinant Mouse CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse CD47 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln19-Lys140.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q61735\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Lys140\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 40.60 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Mouse SIRP alpha, His Tag at 1ug\/ml (100ul\/well) on the plate. Dose response curve for Mouse CD47, hFc Tag with the EC50 of 0.26ug\/ml determined by ELISA (QC Test). The affinity constant of 28.33 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123576103137,"sku":"BLK-02446P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20220111113306.png?v=1715135655"},{"product_id":"recombinant-mouse-cd47-protein-active-blk-02451p","title":"Recombinant Mouse CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse CD47 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln19-Lys140.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q61735\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Lys140\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 14.9 kDa. Due to glycosylation, the protein migrates to 35-50 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe affinity constant of 1.33 uM as determined in SPR assay (Biacore T200). Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123576430817,"sku":"BLK-02451P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1563180772587642.png?v=1715135671"},{"product_id":"biotinylated-human-cd47-protein-active-blk-02455p","title":"Biotinylated Human CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human CD47 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains GIn19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q08722\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGIn19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 18.38 kDa. Due to glycosylation, the protein migrates to 42-52 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Biotinylated Human CD47, His Tag at 2ug\/ml (100ul\/well) on the streptavidin precoated plate (5ug\/ml). Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 3.4ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123576561889,"sku":"BLK-02455P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20221025131021.png?v=1715135683"},{"product_id":"recombinant-human-cd47-protein-active-blk-02462p","title":"Recombinant Human CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human CD47 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q08722\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 40.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human SIRP alpha, His Tag at 1ug\/ml (100ul\/Well) on the plate. Dose response curve for Human CD47, hFc Tag with the EC50 of 5.0ng\/ml determined by ELISA (QC Test). The affinity constant of 13.8nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123576824033,"sku":"BLK-02462P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20211214180500.png?v=1715135705"},{"product_id":"recombinant-human-cd47-protein-active-blk-02466p","title":"Recombinant Human CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human CD47 is expressed from HEK293 with His tag at the C-Terminus.It contains Gln19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e Q08722\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGln19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 14.5 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human CD47, His Tag at 2ug\/ml (100ul\/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 82.1ng\/ml determined by ELISA (QC Test). The affinity constant of 18.9nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123577118945,"sku":"BLK-02466P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20211214175459.png?v=1715135722"},{"product_id":"cd47-recombinant-monoclonal-antibody-blc-06671a","title":"CD47 Recombinant Monoclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47 Recombinant Monoclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant antibody against CD47 was produced using a synthesized peptide derived from human CD47 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IHC, IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ08722\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47 (Antigenic surface determinant protein OA3) (Integrin-associated protein) (IAP) (Protein MER6) (CD antigen CD47), CD47, MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eA synthesized peptide derived from human CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAffinity-chromatography purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46137026281697,"sku":"BLC-06671A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-RA802124A0HU-WB_8cf994e9-23a4-4527-af70-4d822d0192b4.jpg?v=1738978461"},{"product_id":"human-cd47-polyclonal-antibody-blc-03383a","title":"Rabbit anti-Human CD47 Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human CD47 Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against CD47 was raised in rabbit using the Synthetic peptide of Human CD47 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eQ08722\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen identified by monoclonal antibody 1D8 antibody; Antigenic surface determinant protein OA3 antibody; CD 47 antibody; CD47 antibody; CD47 antigen (Rh-related antigen; integrin-associated signal transducer) antibody; CD47 antigen antibody; CD47 glycoprotein antibody; CD47 molecule antibody; CD47_HUMAN antibody; IAP antibody; Integrin Associated Protein antibody; Integrin associated signal transducer antibody; Integrin-associated protein antibody; Leukocyte surface antigen CD47 antibody; MER 6 antibody; MER6 antibody; OA 3 antibody; OA3 antibody; OTTHUMP00000041152 antibody; OTTHUMP00000041153 antibody; Protein MER6 antibody; Rh related antigen antibody; Surface antigen identified by monoclonal antibody 1D8 antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic peptide of Human CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46137325977825,"sku":"BLC-03383A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA445679-P_ea35fc7a-dea6-4337-9b4f-303ce3e3dc39.jpg?v=1738983801"},{"product_id":"recombinant-mouse-iap-oa3-cd47-protein-blt-03630p","title":"Mouse Cd47 (Leukocyte Surface Antigen Cd47) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse IAP\/OA3\/CD47 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse IAP\/OA3\/CD47 protein includes amino acids 19-158aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ61735\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCd47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Prote\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e42.8 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19-158aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eC-Fc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701157548257,"sku":"BLT-03630P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsei9aup1i9l1o00j.jpg?v=1753343679"},{"product_id":"recombinant-mouse-iap-oa3-cd47-protein-blt-03830p","title":"Mouse Cd47 (Leukocyte Surface Antigen Cd47) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse IAP\/OA3\/CD47 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse IAP\/OA3\/CD47 protein includes amino acids 19-158aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ61735\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCd47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Prote\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e16.7 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19-158aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701201457377,"sku":"BLT-03830P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsel32r3qgi1fsbj.jpg?v=1753344542"},{"product_id":"recombinant-human-cd47-protein-blt-04835p","title":"Human CD47 (Leukocyte Surface Antigen Cd47) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Leukocyte Surface Antigen CD47\/IAP\/OA3 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human Leukocyte Surface Antigen CD47\/IAP\/OA3 protein includes amino acids 19-139aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte Surface Antigen CD47; Antigenic Surface Determinant Protein OA3; Integrin-Associated Prote\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e41.9 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eC-Fc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer, Immunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVery broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701435224289,"sku":"BLT-04835P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsggi7ulrsh1ui7j.jpg?v=1753348863"},{"product_id":"recombinant-human-cd47-protein-blt-05909p","title":"Human CD47 (Leukocyte Surface Antigen Cd47) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human CD47 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human CD47 protein includes amino acids 1-139aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIAP;MER6;OA3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e14.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer, Immunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVery broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701633306849,"sku":"BLT-05909P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsdru0pltpvpggj.jpg?v=1753353365"},{"product_id":"recombinant-human-cd47-protein-blt-06830p","title":"Human CD47 (Leukocyte Surface Antigen Cd47) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human CD47 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human CD47 protein includes amino acids 1-139aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ08722\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLeukocyte surface antigen CD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIAP;MER6;OA3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e40.7 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-139aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eC-Fc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer, Immunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHas a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and\/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCell membrane; Multi-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVery broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701766017249,"sku":"BLT-06830P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsee7hn91qvmtivj.jpg?v=1753357244"},{"product_id":"fitc-labeled-human-cd47-recombinant-protein-blk-03321p","title":"Recombinant FITC-Labeled Human CD47 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant FITC-Labeled Human CD47 Protein is expressed from HEK293 with His tag at the C-terminus.It contains Gln19-Pro139.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ08722-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Bis-Tris PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eC-His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGln19-Pro139\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe protein has a predicted MW of 14.5 kDa. Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSupplied as 0.22 um filtered solution in PBS (pH 7.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLess than 1 EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eImmobilized FITC-Labeled Human CD47, His Tag at 1ug\/ml (100ul\/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 77.4ng\/ml determined by ELISA (QC Test).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFluorophore\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFITC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBiotinylated\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eShipped with dry ice.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eValid for 6 months from date of receipt when stored at -80°C.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":47339256742113,"sku":"BLK-03321P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20241031170518.png?v=1761765554"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/collections\/Protein_CD47_PDB_2JJS.png?v=1778520501","url":"https:\/\/www.betalifesci.com\/collections\/cd47-protein-overview-applications-selection-guide.oembed","provider":"Beta LifeScience","version":"1.0","type":"link"}